$4.56
-0.01 (-0.16%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ATHE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 expanded access
Held by 1 tracked-famous manager (CITADEL ADVISORS LLC) · FINRA short interest 2.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in FranceNCT07729852Incidence, Severity, and Relationship of Adverse Events (AEs) and Serious Adverse Events (SAEs)Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: ATH434 | Multiple System Atrophy | 5 | Jul 2029 | ≤ 1,077 d | 2026-07-28 |
| A Biomarker Study of ATH434 in Participants With MSANCT05864365Change in brain volume as measured by MRIOpen-label · Treatment | Phase 2 | Completed | Drug: ATH434 | Multiple System Atrophy | 10 | 2025-02-26actual | — | 2025-04-01 |
| Study of ATH434 in Participants with Multiple System AtrophyNCT05109091Change in iron content as measured by brain MRIRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ATH434 dose level 1, ATH434 dose level 2, Placebo | Multiple System Atrophy | 77 | 2024-11-28actual | — | 2024-12-13 |
| Post-Trial Access to ATH434 for Patients With Multiple System AtrophyNCT07531433expanded access | — | Available | Drug: ATH434 | Multiple System Atrophy | — | — | — | 2026-04-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19